Biotech Values

[DewDiligence]

Re: Lambda in HBV

I think Lambda should now focus on HBV rather than HCV given Ribavirin doesn't add anything to HBV seroconversion.

Inasmuch as the partnership agreement between ZGEN and BMY has $287M of potential milestone payments for non-HCV indications (#msg-34768182), ZGEN has considerable upside if BMY should decide to pursue a Lambda program in HBV. On the other hand, BMY might be reluctant to move aggressively in HBV due to fear of cannibalizing sales of Baraclude.